{"id":5783,"date":"2024-03-24T01:10:58","date_gmt":"2024-03-24T00:10:58","guid":{"rendered":"https:\/\/www.cooperpharma.digitalia-solutions.com\/maroc\/?page_id=5783"},"modified":"2024-03-25T14:05:30","modified_gmt":"2024-03-25T13:05:30","slug":"our-sites","status":"publish","type":"page","link":"https:\/\/www.cooperpharma.digitalia-solutions.com\/maroc\/en\/our-sites\/","title":{"rendered":"Production sites & Laboratories"},"content":{"rendered":"
\n\t\t\t\t\t\t\t
\n\t\t\n\t\t
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
\n\t\t
\n
\n \t\t
\n\t\t\t\t
\n\t\t\t
\r\n
Production sites<\/div>\r\n
<\/div>\r\n

Tit Mellil site<\/h3>\r\n
<\/div>\r\n<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\n\t\t
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
\n\t\t
\n
\n \t\t
\n\t\t\t\t
\n\t\t\t
\r\n \"s\"
<\/div>\r\n
\r\n
<\/div>
Tit Mellil<\/div> <\/div>\r\n<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t <\/div>\n <\/div>\n
\n
\n \t\t
\n\t\t\t\t
\n\t\t\t
\r\n
\r\n
\r\n
Covering an area of 20,000 m\u00b2 and employing a third of the group's workforce (500 people), the Tit Mellil plant is specialised in the manufacture of solid, liquid and pasty products. It produces more than 45 million units annually.<\/div>\r\n
<\/div>\r\n
<\/span> <\/span> <\/div><\/div>
It is GMP, BPF, AFSSAPS, Saudi FDA and Libya approved<\/div>
<\/div><\/div><\/div><\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t <\/div>\n <\/div>\n \t\t <\/div>\n <\/div>\n\t\t <\/div>\n <\/div>\n \t\t <\/div>\n <\/div>\n\t\t
\n\t\t\n\t\t
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
\n\t\t
\n
\n <\/div>\n <\/div>\n
\n
\n <\/div>\n <\/div>\n \t\t <\/div>\n <\/div>\n\t\t
\n\t\t\n\t\t
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
\n\t\t
\n
\n \t\t
\n\t\t\t\t
\n\t\t\t
\r\n
MC Pharma<\/div>\r\n
<\/div>\r\n

MC Pharma<\/h3>\r\n
<\/div>\r\n<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\n\t\t
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
\n\t\t
\n
\n \t\t
\n\t\t\t\t
\n\t\t\t
\r\n
\r\n
\r\n
Created in 2007, MC Pharma produces effervescent tablets in compliance with specific standards and conditions, such as the installation of a dry air system.<\/div>\r\n
<\/div>\r\n
<\/span> <\/span> <\/div><\/div>
Cooper Pharma holds a strategic stake in MC Pharma.<\/div>
<\/div><\/div><\/div><\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t <\/div>\n <\/div>\n
\n
\n \t\t
\n\t\t\t\t
\n\t\t\t
\r\n \"COOPER
<\/div>\r\n
\r\n
<\/div>
MC Pharma<\/div> <\/div>\r\n<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t <\/div>\n <\/div>\n \t\t <\/div>\n <\/div>\n\t\t <\/div>\n <\/div>\n \t\t <\/div>\n <\/div>\n\t\t
\n\t\t\n\t\t
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
\n\t\t
\n
\n \t\t
\n\t\t\t\t
\n\t\t\t
\n
\n
\n
\r\n
\r\n
Gynebio Pharma<\/div>\r\n
<\/div>\r\n

Gynebio Pharma<\/h2>\r\n
<\/div>\r\n <\/div><\/div>\r\n
\n
\n
Launched in 2019, Gynebio Pharma is the1st site dedicated to the manufacture of contraceptive hormones in Africa.<\/div>
<\/div><\/div><\/div>\n <\/div>\n \n <\/div>\n <\/div>\n <\/div>\n
\n
+90 years of experience<\/div><\/div>
\"\"<\/div>
\n <\/svg><\/svg> <\/div>\n <\/div>
\n
\r\n
\r\n
\r\n
<\/div><\/span><\/div>\r\n <\/div>\r\n
<\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\n <\/div>\n<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t <\/div>\n <\/div>\n \t\t <\/div>\n <\/div>\n\t\t
\n\t\t\n\t\t
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
\n\t\t
\n
\n \t\t
\n\t\t\t\t
\n\t\t\t
\r\n
IDC Pharma<\/div>\r\n
<\/div>\r\n

IDC Pharma<\/h3>\r\n
<\/div>\r\n<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\n\t\t
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
\n\t\t
\n
\n \t\t
\n\t\t\t\t
\n\t\t\t
\r\n \"\"
<\/div>\r\n
\r\n
<\/div>
IDC\n PHARMA<\/div> <\/div>\r\n<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t
\n
\n
\"cooperpharma\"<\/div>
\r\n
\r\n
\r\n
<\/div><\/span><\/div>\r\n <\/div>\r\n
<\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\n <\/div>\n
\n
\n <\/div>\n <\/div>\n<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t <\/div>\n <\/div>\n
\n
\n \t\t
\n\t\t\t\t
\n\t\t\t
\r\n
\r\n
\r\n
It's the Group's laboratory dedicated to Incremental Research and Development. Its mission is to develop galenic formulations:<\/div>\r\n
<\/div>\r\n
<\/span> <\/span> <\/div><\/div>
Medicines with added-value formulations<\/div>
<\/div><\/div><\/div><\/div>\r\n
<\/span> <\/span> <\/div><\/div>
\u00ab Generics plus \u00bb<\/div>
<\/div><\/div><\/div><\/div>\r\n
<\/span> <\/span> <\/div><\/div>
Associations<\/div>
<\/div><\/div><\/div><\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t <\/div>\n <\/div>\n \t\t <\/div>\n <\/div>\n\t\t <\/div>\n <\/div>\n \t\t <\/div>\n <\/div>\n\t\t
\n\t\t\n\t\t
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
\n\t\t
\n
\n \t\t
\n\t\t\t\t
\n\t\t\t
\n
\n
\n
\r\n
\r\n
CIPLA JV<\/div>\r\n
<\/div>\r\n

CIPLA JV<\/h2>\r\n
<\/div>\r\n <\/div><\/div>\r\n
\n
\n
Cooper Pharma is increasing its ownership in the Cipla Maroc joint venture from 15.8% to 24.9%. This strategic decision aims to strengthen Cooper Pharma's position as a leader in respiratory and central nervous system therapies, ensuring continued access to quality care for the Moroccan population.<\/div>
<\/div><\/div><\/div>\n <\/div>\n \n <\/div>\n <\/div>\n <\/div>\n
\n
+90 ans d'exp\u00e9rience<\/div><\/div>
\"\"<\/div>
\n <\/svg><\/svg> <\/div>\n <\/div>
\n
\r\n
\r\n
\r\n
<\/div><\/span><\/div>\r\n <\/div>\r\n
<\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\n <\/div>\n<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t <\/div>\n <\/div>\n \t\t <\/div>\n <\/div>\n\t\t
\n\t\t\n\t\t
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
\n\t\t
\n
\n \t\t
\n\t\t\t\t
\n\t\t\t
\r\n
\r\n
\r\n
\r\n
\r\n \r\n \"\" <\/a>\r\n <\/div>\r\n
\r\n \r\n \"\" <\/a>\r\n <\/div>\r\n
\r\n \r\n \"\" <\/a>\r\n <\/div>\r\n
\r\n \r\n \"\" <\/a>\r\n <\/div>\r\n
\r\n \r\n \"\" <\/a>\r\n <\/div>\r\n
\r\n \r\n \"\" <\/a>\r\n <\/div>\r\n
\r\n \r\n \"\" <\/a>\r\n <\/div>\r\n
\r\n \r\n \"\" <\/a>\r\n <\/div>\r\n <\/div>\r\n
<\/div>\r\n
<\/div>\r\n
<\/div>\r\n <\/div>\r\n <\/div>\r\n<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t